Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

1,535

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

August 31, 2003

Study Completion Date

July 31, 2014

Conditions
Breast Cancer
Interventions
DRUG

5-FU, epirubicin and cyclophosphamide

Tailored dose escalation of epirubicin and cyclophosphamide.

Sponsors
All Listed Sponsors
collaborator

Scandinavian Breast Group

OTHER

collaborator

Danish Breast Cancer Cooperative Group

OTHER

collaborator

Swedish Cancer Society

OTHER

collaborator

Swedish Cancer Foundation

OTHER

collaborator

Pharmacia Pharmaceutical Company

UNKNOWN

collaborator

Swedish Breast Cancer Group

OTHER

lead

Henrik Lindman

OTHER